Group 1 - The biotechnology company has launched a new direct-to-patient program called AmgenNow, which initially focuses on its drug Repatha [1]

Group 1 - The company is facing intense competition within the industry, which is impacting its pricing strategies and customer acquisition efforts [1]

Weiss, who once said she was done with legacy media, is to take control of CBS News's editorial vision, aiming for "news that reflects reality.†...

Such listings surged starting last year. Now Nasdaq says it wants to tighten its standards. ...

Five-year agreement will challenge Nvidia's market dominance, as OpenAI plans deployment of AMD's new MI450 chips. ...

Core Viewpoint - The article indicates that there are signs of a modestly resilient economy in the U.S. despite challenges such as tariffs and political uncertainty [1] Group 1 - The U.S. economy shows resilience in the face of external pressures [1]

U.S. stock futures started the week higher even as the U.S. federal government shutdown dragged on into another week and stocks in Japan rose sharply. ...

Japanese stocks surge and yen sinks after Takaichi wins ruling party leadership ...

For Europe's central bankers, President Trump's tariff blitz has been a bit of a nonevent. ...

Its new retail voting program is no 'power grab.' ...